Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
May 03, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology CHARLESTON, S.C., May 03, 2021 (GLOBE...
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
April 28, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 22, 2021 16:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
March 15, 2021 08:05 ET
|
Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of intellectual property for the development of a...
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
March 11, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which...
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
February 24, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
February 19, 2021 13:25 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
February 16, 2021 22:00 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
February 16, 2021 17:19 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...